vs
Side-by-side financial comparison of GSI TECHNOLOGY INC (GSIT) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $6.1M, roughly 1.5× GSI TECHNOLOGY INC). GSI TECHNOLOGY INC runs the higher net margin — -49.7% vs -60.3%, a 10.6% gap on every dollar of revenue. On growth, GSI TECHNOLOGY INC posted the faster year-over-year revenue change (12.2% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-8.2M). Over the past eight quarters, GSI TECHNOLOGY INC's revenue compounded faster (8.6% CAGR vs -6.7%).
Triad GSI is an American voting machine vendor based in Xenia, Ohio. Their main products are election-related computer hardware and software for counting ballots, as well as voter registration.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
GSIT vs PLX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.1M | $9.1M |
| Net Profit | $-3.0M | $-5.5M |
| Gross Margin | 52.7% | 49.4% |
| Operating Margin | -113.7% | -51.1% |
| Net Margin | -49.7% | -60.3% |
| Revenue YoY | 12.2% | -49.9% |
| Net Profit YoY | 25.0% | -184.8% |
| EPS (diluted) | $-0.09 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.1M | $9.1M | ||
| Q3 25 | $6.4M | $17.9M | ||
| Q2 25 | $6.3M | $15.7M | ||
| Q1 25 | $5.9M | $10.1M | ||
| Q4 24 | $5.4M | $18.2M | ||
| Q3 24 | $4.5M | $18.0M | ||
| Q2 24 | $4.7M | $13.5M | ||
| Q1 24 | $5.2M | — |
| Q4 25 | $-3.0M | $-5.5M | ||
| Q3 25 | $-3.2M | $2.4M | ||
| Q2 25 | $-2.2M | $164.0K | ||
| Q1 25 | $-2.2M | $-3.6M | ||
| Q4 24 | $-4.0M | $6.5M | ||
| Q3 24 | $-5.5M | $3.2M | ||
| Q2 24 | $1.1M | $-2.2M | ||
| Q1 24 | $-4.3M | — |
| Q4 25 | 52.7% | 49.4% | ||
| Q3 25 | 54.8% | 53.4% | ||
| Q2 25 | 58.1% | 62.5% | ||
| Q1 25 | 56.1% | 19.1% | ||
| Q4 24 | 54.0% | 78.7% | ||
| Q3 24 | 38.6% | 53.4% | ||
| Q2 24 | 46.3% | 29.8% | ||
| Q1 24 | 51.6% | — |
| Q4 25 | -113.7% | -51.1% | ||
| Q3 25 | -49.5% | 11.9% | ||
| Q2 25 | -34.6% | 7.5% | ||
| Q1 25 | -38.7% | -41.0% | ||
| Q4 24 | -74.9% | 39.6% | ||
| Q3 24 | -122.7% | 22.2% | ||
| Q2 24 | 23.1% | -18.0% | ||
| Q1 24 | -87.6% | — |
| Q4 25 | -49.7% | -60.3% | ||
| Q3 25 | -49.4% | 13.2% | ||
| Q2 25 | -35.3% | 1.0% | ||
| Q1 25 | -37.9% | -35.8% | ||
| Q4 24 | -74.4% | 35.6% | ||
| Q3 24 | -120.0% | 18.0% | ||
| Q2 24 | 23.1% | -16.4% | ||
| Q1 24 | -83.9% | — |
| Q4 25 | $-0.09 | $-0.06 | ||
| Q3 25 | $-0.11 | $0.03 | ||
| Q2 25 | $-0.08 | $0.00 | ||
| Q1 25 | $-0.09 | $-0.05 | ||
| Q4 24 | $-0.16 | $0.10 | ||
| Q3 24 | $-0.21 | $0.03 | ||
| Q2 24 | $0.04 | $-0.03 | ||
| Q1 24 | $-0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.7M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $83.6M | $48.2M |
| Total Assets | $98.5M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.7M | $14.7M | ||
| Q3 25 | $25.3M | $13.6M | ||
| Q2 25 | $22.7M | $17.9M | ||
| Q1 25 | $13.4M | $19.5M | ||
| Q4 24 | $15.1M | $19.8M | ||
| Q3 24 | $18.4M | $27.4M | ||
| Q2 24 | $21.8M | $23.4M | ||
| Q1 24 | $14.4M | — |
| Q4 25 | $83.6M | $48.2M | ||
| Q3 25 | $38.6M | $52.9M | ||
| Q2 25 | $37.4M | $49.9M | ||
| Q1 25 | $28.2M | $45.2M | ||
| Q4 24 | $29.9M | $43.2M | ||
| Q3 24 | $33.3M | $32.4M | ||
| Q2 24 | $38.0M | $28.6M | ||
| Q1 24 | $36.0M | — |
| Q4 25 | $98.5M | $82.3M | ||
| Q3 25 | $52.0M | $82.3M | ||
| Q2 25 | $50.5M | $78.5M | ||
| Q1 25 | $43.3M | $73.9M | ||
| Q4 24 | $44.1M | $73.4M | ||
| Q3 24 | $47.4M | $61.6M | ||
| Q2 24 | $52.3M | $91.5M | ||
| Q1 24 | $42.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.9M | $2.0M |
| Free Cash FlowOCF − Capex | $-8.2M | $1.6M |
| FCF MarginFCF / Revenue | -134.4% | 17.8% |
| Capex IntensityCapex / Revenue | 4.9% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.5M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.9M | $2.0M | ||
| Q3 25 | $-887.0K | $-3.7M | ||
| Q2 25 | $-1.7M | $-5.2M | ||
| Q1 25 | $-1.7M | $-5.1M | ||
| Q4 24 | $-3.6M | $4.0M | ||
| Q3 24 | $-3.5M | $4.1M | ||
| Q2 24 | $-4.3M | $-3.6M | ||
| Q1 24 | $-7.1M | — |
| Q4 25 | $-8.2M | $1.6M | ||
| Q3 25 | $-906.0K | $-4.2M | ||
| Q2 25 | $-1.7M | $-5.7M | ||
| Q1 25 | $-1.7M | $-5.4M | ||
| Q4 24 | $-3.6M | $3.6M | ||
| Q3 24 | $-3.5M | $4.0M | ||
| Q2 24 | $-4.3M | $-3.8M | ||
| Q1 24 | $-7.2M | — |
| Q4 25 | -134.4% | 17.8% | ||
| Q3 25 | -14.1% | -23.7% | ||
| Q2 25 | -27.6% | -36.2% | ||
| Q1 25 | -28.3% | -53.0% | ||
| Q4 24 | -66.1% | 19.6% | ||
| Q3 24 | -76.6% | 22.4% | ||
| Q2 24 | -92.0% | -28.1% | ||
| Q1 24 | -139.0% | — |
| Q4 25 | 4.9% | 4.4% | ||
| Q3 25 | 0.3% | 2.8% | ||
| Q2 25 | 0.3% | 2.8% | ||
| Q1 25 | 0.1% | 3.0% | ||
| Q4 24 | 0.1% | 2.3% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 0.7% | 1.3% | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | -3.96× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GSIT
| Distribution | $5.6M | 92% |
| Other | $459.0K | 8% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
